1-15 of 15
Enrico Carminati
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Comparing Outcomes between CPX-351 and Fludarabine-Based Induction in Secondary Acute Myeloid Leukemia in the Real-World Setting: The Prognostic Role of Measurable Residual Disease

Carola Riva, Paola Minetto, Maria Chies, Elena Maio, Ylenia Azzanelli, Giada Zecchetti, Nicoletta Colombo, Sara Rosellini, Alessia Parodi, Elisabetta Tedone, Enrico Carminati, Giuseppina Fugazza, Paolo Nozza, Michele Cea, Roberto Massimo Lemoli, Fabio Guolo
Journal: Blood
Blood (2024) 144 (Supplement 1): 1482.
https://doi.org/10.1182/blood-2024-198174
Published: 2024
Journal Articles

High Risk Mutations in Critical Genes Do Not Significantly Affect Remission Rates and Minimal Residual Disease Clearance in Acute Myeloid Leukemia Patients Receiving CPX-351 Induction

Fabio Guolo, Carola Riva, Maria Chies, Chiara Vernarecci, Ylenia Azzanelli, Nicoletta Colombo, Sara Rosellini, Alessia Parodi, Elisabetta Tedone, Enrico Carminati, Francesco Puglisi, Clara Nurra, Giuseppina Fugazza, Michele Cea, Roberto Massimo Lemoli, Paola Minetto
Journal: Blood
Blood (2024) 144 (Supplement 1): 1478.
https://doi.org/10.1182/blood-2024-198187
Published: 2024
Journal Articles

Excellent Outcome in NPM1- mutated Acute Myeloid Leukemia Patients Receiving Intensified Fludarabine-Based Induction Is Not Affected By Secondary Type Mutations and Other High Risk Aberrations

Paola Minetto, Carola Riva, Enrico Carminati, Ylenia Azzanelli, Francesco Puglisi, Clara Nurra, Giuseppina Fugazza, Antonia Cagnetta, Michele Cea, Roberto Massimo Lemoli, Fabio Guolo
Journal: Blood
Blood (2024) 144 (Supplement 1): 4239.
https://doi.org/10.1182/blood-2024-198171
Published: 2024
Journal Articles

Real World Evidence of Efficacy of CPX-351 in Secondary Acute Myeloid Leukemia Defined According to Who 2022 Classification

Carola Riva, Paola Minetto, Maria Chies, Chiara Vernarecci, Giada Zecchetti, Elena Maio, Ylenia Azzanelli, Nicoletta Colombo, Sara Rosellini, Alessia Parodi, Elisabetta Tedone, Enrico Carminati, Francesco Puglisi, Clara Nurra, Giuseppina Fugazza, Paolo Nozza, Michele Cea, Roberto Massimo Lemoli, Fabio Guolo
Journal: Blood
Blood (2024) 144 (Supplement 1): 1471.
https://doi.org/10.1182/blood-2024-197943
Published: 2024
Journal Articles

High Efficacy and Feasibility of a Full Pediatric Induction in Adults Aged up to 55 Years with Philadelphia-Negative Acute Lymphoblastic Leukemia

Chiara Vernarecci, Elena Maio, Mattia Montanari, Francesco Puglisi, Clara Nurra, Maurizio Miglino, Nicoletta Colombo, Enrico Carminati, Giada Zecchetti, Maria Chies, Beatrice Ferro, Massimo Zucchetti, Antonia Cagnetta, Michele Cea, Elisabetta Tedone, Roberto Massimo Lemoli, Fabio Guolo, Paola Minetto
Journal: Blood
Blood (2023) 142 (Supplement 1): 5879.
https://doi.org/10.1182/blood-2023-185082
Published: 2023
Journal Articles

Mutational Burden in High Risk Genes Do Not Affect Remission Rates and MRD Clearance in Elderly AML Patients Receiving CPX-351 Induction

Carola Riva, Paola Minetto, Enrico Carminati, Maria Chies, Chiara Vernarecci, Beatrice Ferro, Elena Maio, Giada Zecchetti, Michela Frello, Maurizio Miglino, Elisabetta Tedone, Nicoletta Colombo, Clara Nurra, Francesco Puglisi, Antonia Cagnetta, Michele Cea, Giuseppina Fugazza, Roberto Massimo Lemoli, Fabio Guolo
Journal: Blood
Blood (2023) 142 (Supplement 1): 6016.
https://doi.org/10.1182/blood-2023-186555
Published: 2023
Journal Articles

Single Agent Tagraxofusp in Relapsed/Refractory CD123-Positive Acute Myeloid Leukemia: A Preliminary Analysis of Italian Gimema AML2020 Trial

Paola Minetto, Sara Rosellini, Fabio Guolo, Elisabetta Tedone, Ernesta Audisio, Chiara Cattaneo, Monica Bocchia, Nicola Fracchiolla, Maria Paola Martelli, Enrico Crea, Enrico Carminati, Livia Gorreo Renzulli, Giuseppina Fugazza, Alfonso Piciocchi, Giovanni Ottonelli, Maurizio Miglino, Michele Cea, Antonio Curti, Livio Pagano, Adriano Venditti, Tariq Mughal, Roberto Massimo Lemoli
Journal: Blood
Blood (2023) 142 (Supplement 1): 2918.
https://doi.org/10.1182/blood-2023-189417
Published: 2023
Journal Articles

Prognostic Relevance of Minimal Residual Disease in Therapy Related and Secondary Acute Myeloid Leukemia Receiving CPX-351 or Fludarabine-Based Induction

Fabio Guolo, Paola Minetto, Carola Riva, Chiara Vernarecci, Monica Passannante, Francesca Parodi, Michela Frello, Elena Maio, Beatrice Ferro, Maria Chies, Maurizio Miglino, Elisabetta Tedone, Nicoletta Colombo, Enrico Carminati, Clara Nurra, Francesco Puglisi, Antonia Cagnetta, Michele Cea, Roberto Massimo Lemoli
Journal: Blood
Blood (2022) 140 (Supplement 1): 8930–8931.
https://doi.org/10.1182/blood-2022-169394
Published: 2022
Journal Articles

Prognostic Impact of Minimal Residual Disease Assessment in Elderly Patients with Secondary Acute Myeloid Leukemia. a Comparison between CPX-351 and Intensified Fludarabine-Based Regimens

Fabio Guolo, Paola Minetto, Marino Clavio, Maurizio Miglino, Riccardo Marcolin, Monica Passannante, Carola Riva, Michela Frello, Chiara Vernarecci, Elisabetta Tedone, Nicoletta Colombo, Enrico Carminati, Girolamo Pugliese, Clara Nurra, Antonia Cagnetta, Michele Cea, Marco Gobbi, Roberto M. Lemoli
Journal: Blood
Blood (2021) 138 (Supplement 1): 3442.
https://doi.org/10.1182/blood-2021-153060
Published: 2021
Journal Articles

Next Generation Sequencing and Microrna Assay in a Cohort of Patients Affected By Myelodysplastic Syndromes. an Analysis of Clinical and Genotypic Features

Daniele Avenoso, MD, Margherita Squillario, Annalisa Barla, Alessandro Verri, Enrico Carminati, Clara Nurra, Elisabetta Todisco, MD PhD, Federica Gigli, MD, Giuliana Gregato, Claudia Poletti, Francesco Bertolini, MD PhD, Ghulam J. Mufti, MBBS, FRCP, FRCPath, DM, Mili Shah, FRCPath, Maurizio Miglino
Journal: Blood
Blood (2019) 134 (Supplement_1): 5414.
https://doi.org/10.1182/blood-2019-130153
Published: 2019
Journal Articles

Fludarabine, High Dose Cytarabine and Idarubicin-Based Induction Is Highly Effective in Young AML Patients with Concomitant NPM1 and FLT3-ITD Mutation Irrespectively of FLT3-ITD Allelic Burden

Paola Minetto, MD, Anna Candoni, MD, Fabio Guolo, MD, Marino Clavio, MD, Maria Elena Zannier, MD, Maurizio Miglino, PhD, Maria Vittoria Dubbini, MD, Enrico Carminati, Anna Sicuranza, PhD, Sara Ciofini, Elisabetta Tedone, Nicoletta Colombo, PhD, Girolamo Pugliese, Riccardo Marcolin, MD, Filippo Ballerini, MD, Michele Cea, Marco Gobbi, MD, Monica Bocchia, Renato Fanin, MD, Roberto Massimo Lemoli, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3828.
https://doi.org/10.1182/blood-2019-131303
Published: 2019
Journal Articles

Addition of the Anti-CD33 Monoclonal Antibody Mylotarg to Fludarabine/High Dose Cytarabine - Based Induction Significantly Improves Outcome in Patient Affected By FLT3-ITD Positive Cytogenetically Normal Acute Myeloid Leukemia

Paola Minetto, MD, Anna Candoni, MD, Fabio Guolo, MD, Marino Clavio, MD, Maria Elena Zannier, MD, Maurizio Miglino, PhD, Maria Vittoria Dubbini, MD, Enrico Carminati, Anna Sicuranza, PhD, Sara Ciofini, Elisabetta Tedone, Paola Contini, Clara Nurra, Monica Passannante, MD, Filippo Ballerini, MD, Antonia Cagnetta, MD, Marco Gobbi, MD, Monica Bocchia, Renato Fanin, MD, Roberto Massimo Lemoli, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1365.
https://doi.org/10.1182/blood-2019-131420
Published: 2019
Journal Articles

Pre-Transplant Minimal Residual Disease Evaluation Performed By Molecular WT1-Based or Multicolor Flow Cytometry Assessment Overcomes the Prognostic Value of Cytogenetic and Molecular Risk Factors at Diagnosis in Advanced Acute Myeloid Leukemia Patients

Fabio Guolo, MD, Paola Minetto, MD, Marino Clavio, MD, Nicoletta Colombo, PhD, Annalisa Kunkl, MD, Enrico Carminati, Carmen Di Grazia, MD, Anna Maria Raiola, MD, Filippo Ballerini, MD, Maurizio Miglino, PhD, Emanuele Angelucci, Roberto M Lemoli, MD, Marco Gobbi, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3316.
https://doi.org/10.1182/blood.V130.Suppl_1.3316.3316
Published: 2017
Journal Articles

Early Minimal Residual Disease Assessment after Acute Myeloid Leukemia Induction with Fludarabine Cytarabine and Idarubicin (FLAI) Provides the Most Useful Prognostic Information

Paola Minetto, MD, Fabio Guolo, MD, Marino Clavio, MD, Annalisa Kunkl, MD, Nicoletta Colombo, PhD, Enrico Carminati, Giuseppina Fugazza, Simona Matarese, MD, Daniela Guardo, MD, Filippo Ballerini, MD, Carmen Di Grazia, MD, Anna Maria Raiola, MD, Antonia Cagnetta, MD, Michele Cea, Maurizio Miglino, PhD, Roberto Massimo Lemoli, MD, Marco Gobbi, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 5047.
https://doi.org/10.1182/blood.V130.Suppl_1.5047.5047
Published: 2017
Journal Articles

Minimal Residual Disease Assessment May Drive Post Remission Therapy in Acute Myeloid Leukemia. It's Time for MRD-Driven Therapy

Paola Minetto, MD, Fabio Guolo, MD, Marino Clavio, MD, Annalisa Kunkl, MD, Filippo Ballerini, MD, Nicoletta Colombo, PhD, Enrico Carminati, Giuseppina Fugazza, Giordana Pastori, MD, Simona Matarrese, Carmen Di Grazia, MD, Anna Maria Raiola, MD, Andrea Bacigalupo, MD, Roberto Massimo Lemoli, MD, Maurizio Miglino, PhD, Marco Gobbi, MD
Journal: Blood
Blood (2016) 128 (22): 2895.
https://doi.org/10.1182/blood.V128.22.2895.2895
Published: 2016